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There is a long-standing controversy over whether melano-
cytes in vitiligo lesions are actually lost or are still present but 
inactivated. Resolving this matter is essential for understand-
ing the underlying pathology and for the development of 
treatment. Standard methods of detecting melanocytes are 
based on active melanin synthesis. However, it is possible that 
inactive melanocytes remain in the lesions. There are no 
methods presently available to detect such dormant melano-
cytes. Using a panel of one polyclonal and 17 monoclonal 
antibodies directed against melanocytic cells (largely selected 
by the European Organisation for Research and Treatment of 
Cancer Melanoma Group for diagnostic and therapeutic 
V itiligo is a melanin pigmentary disorder of the skin, affecting approximately 1 % of the world population [1,2) . In vitiligo lesions, no melanin pigmentation can be observed. There is a long-standing controversy about the cause of this depigmentation. Theoreti-
cally, lesional melanocytes may have ceased actively producing or 
transferring melanin. Alternatively, melanocytes may be lost from 
the lesions ' altogether. It is important to resolve this controversy 
both for the understanding of vitiligo pathogenesis and for the 
development of treatment. Obviously, if melanocytes have become 
inactive in the lesions, therapy should be aimed at reactivation of 
melanocytes already present. However, if melanocytes are absent, 
therapy should involve the means of repopulating the lesional areas. 
This may be achieved either by stimulation of melanocyte prolifera-
tion and migration from the perilesional areas or from hair follicles 
within the lesional areas [3,4) or by transplantation of autologous 
melanocytes from pigmented areas [5) . Current methods for detect-
ing melanocytes, including both electron microscopic identification 
[6 - 8) and the popular histochemical dihydroxyphenylalanine 
Manuscript received Februaty 9, 1992; accepted for publication January 
13,1993. 
This study was presented in part at the 3rd Annual Meeting of the Euro-
pean Society for Pigment Cell Research, Amsterdam, September 8-11, 
1991, and at the 22nd Annual Meeting of the European Society for Dermato-
logical Research, London, April 4-7,1992. 
Reprint requests to: Dr. P.K. Das, Departments of Dermatology and 
Pathology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amster-
dam, The Netherlands. 
Abbreviations: 
FITC: fluorescein isothiocyanate 
HLA: human leukocyte antigen 
HMW: high molecular weight 
Ig: immunoglobulin 
MHC: major histocompatibility complex 
purposes), we investigated the absence or inactivation of mel-
anocytes in vitiligo by immunohistochemistry. Results using 
this panel of antibodies on frozen skin sections suggest that 
melanocytes are indeed absent in the lesions. However, in 
epidermal split-skin preparations, residual staining was occa-
sionally observed. To determine whether the staining ob-
tained was due to degenerated melanocytes, confocal laser 
scanning microscopy was used. Immunofluorescent staining 
using the antibody NKI-beteb confirmed this to be the case. 
The results presented here strongly suggest that melanocytes 
are indeed lost in vitiligo lesions. ] Invest Dermatol 100:816-
822, 1993 
staining technique [9,10) , are all based on active melanin synthesis. 
It is therefore not surprising that most evidence provided by 
previous investigations supports the view that melanocytes are lost 
in vitiligo lesions. However, residual tyrosinase activity has been 
biochemically demonstrated in lesional vitiligo skin [11). More-
over, we have occasionally found melanocytes in epidermal cell 
cultures obtained from lesional vitiligo skin (unpublished observa-
tion) . Thus, the possibility remains that inactive melanocytes are 
present in lesional vitiligo skin. The objective of the present study 
was to solve the controversy raised by electron microscopic, histo-
chemical, and biochemical observations with a different approach. 
Using a panel of antibodies reactiv.e to melanocytic cells, immunocy-
tochemistry provides a powerful method to detect melanocytes ei-
ther in normal or in reduced amounts, with normal or altered pheno-
type. 
Recently, several antibodies reactive to melanocytic cells have 
been produced, principally for melanoma detection [12 -29). Not 
all markers in the panel are expected to react with normal melano-
cytes . The antibodies were used to perform immunohistochemical 
staining of non-Iesional and lesional vitiligo skin. Should any of the 
antibodies detect lesional melanocytes in their normal distribution 
pattern, this would indicate the presence of dormant melanocytes 
not producing melanin. However, if all melanocyte antigens that 
can be detected by the panel are absent, then it is highly unlikely that 
melanocytes are present in lesional vitiligo skin . Alternatively, mela-
nocytes may be present in reduced numbers. This is difficult to assess 
using frozen sections, because the number of melanocytes present in 
a frozen section from a 4-mm punch biopsy is limited to approxi-
mately 25 (unpublished observation). In contrast, the average num-
ber of melanocytes visible within an epidermal sr.lit-skin prepara-
tion from a 3-mm punch biopsy is 7000 [30. Split skin was 
therefore used to compare the number of melanocytes in normal and 
vitiligo skin. 
Finally, the nature of residual immunostaining within lesional 
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Table I. Demographic Data of Patients· 
Patient 
2 3 4 5 6 7 8 9 10 11 12 
Gender F F F M F F M F F F F M 
J\ge (ye~s) 50 28 25 28 13 48 14 45 52 32 52 66 
Biopsy sIte Leg Arm Leg Arm Arm Arm Arm Arm Arm Arm Leg Arm 
Duration of vitiligo (years) 1 5 2 6 9 9 8 22 50 8 15 3 
Lesion studied S P P S P S S P P P P P 
Medication Herbs Phenylalanine Phenyl- Phenylalanine/ 
/UVA alanine vitamin B6 
-: F, female; M, male; S, stationary (lesion stable for at least 6 months); P, progressive (lesion that has expanded over the last month). 
vitiligo skin was further investigated using confocal laser scanning 
microscopy. This method offers a three-dimensional view of the 
split sk:in under observation by optically cutting th~ ti.ssue .int~ very 
thin slICes [31-33) and can therefore be used to dlstll1gUlsh ll1tact 
cells from cellular debris. 
MATERIALS AND METHODS 
cytospins of Cultured Cells Cytospins of cultured cells were 
made using a Shandon cytospin apparatus (6 min, 600 rpm). Cell 
lines used were M14 melanoma cells [34] and two normal human 
melanocyte lines isolated from foreskin and cultured for four pas-
sages. M14 melanoma cells were cultured in Dulbecco's modified 
Eagle's medium (Flow, Irvine Ayrshire, Scotland) with 5% fetal calf 
serum, 2 mM glutamin (Gibco, Paisley, Scotland), and 100 IU/ml 
penicillin/IOO ,ug/ml streptomycin (Gibco). Normal human mela-
nocytes isolated from foreskin were cultured in Ham's FlO medium 
(Flovv) containing 2 mM glutamin (Gibco), 100 IU/ml penicillin/ 
100 ,ug/ml streptomycin (Gibco), 0.1 mM 3-isobutyl-methyl-
I-xanthine (Sigma, Brussels, Belgium), 10 ng/ml 12-0-tetra-
decanoyl-phorbol 13-acetate (TPA) (Sigma), and Ultroser-G 1 % 
v/v (Gibco) . Cytospins were dried overnight and fixed for 10 min in 
acetone at 4°C. 
Frozen Sections of Human Skin Four-millimeter punch biop-
sies were taken from both lesional and adjacent non-Iesional vitiligo 
skin from seven patients and from surgical material from five 
healthy control subjects. The demographic data are summarized i? 
Table I (patients 1- 7). All patients were white. The biopsy speCi-
mens were s.nap-frozen in liquid nitrogen and then stored at - 80 a C 
until use. Six-micrometer frozen sections were cut uSing an IEC 
cryotome. The sections were air-dried and fixed in 4 a C acetone for 
10 min. 
Epidermal Split-Skin Preparations Three-millimeter punch 
biopsies were taken from five patients (Table I, patients 8-12) and 
from five healthy control subjects, as mentioned above. The epider-
mis was separated from the dermis by soaking in a 2 M NaBr solu-
tion at room temperature for 4 h. The epidermis was attached to a 
Table II. Immunoperoxidase Staining-
Cytospins Frozen Skin Sections 
t>.ntibody Reactive to Group References Melanoma Cells Melanocytes Control Non-Lesional Lesional 
NKl-beteb 100-kOa melanosome associated [12,13J 100%+~++ 100%++ + + 
antigen 
MEL-5 70 - 80-kOa glycoprotein, [14] 4%+ 100% +++ + + 
pigmentation associated 
TMH-2 Tyrosinase-related protein [15,16] 1%+ 90%+~+++ + + 
NKl-C3 25 -1 OO-kOa glycoprotein [12,17] 100%++ 100% +++ + + (differentiation antigen) 
HMB-45 Melanosome-associated cytoplasmic 1 (18) 80%+~+-H- 99%+ +/- +/-
antigen 
G7E2 120-110-kDa glycoprotein 1 [12] 50%+~+++ 40% +-+++ +/- +/-
K-1-2-58 Marker inversely related to tumor 1 [12,19] 1% +-+++ 85%+ + / - +/-
progression 
15-75 75-kOa glycoprotein 2a [12,20] 90%+ 100%+ 
PAL-M2 95-kOa glycoprotein (progression 2a [12,21] 50%+ 100%+ 
marker) 
PAL-Ml Transferrin receptor (C071) 2a [12,21,22] 95% +-++-H- 75%+ .-
B9-12-1 HLA-ABC (MHC class I) 2b [12,23J 100% +++ 99% +-+++ NI NI NI 
5-100 Calcium-binding protein 2b [24] 70% +-++++ 67% +-+++ NI NI NI 
Mel-14 Core protein HMW antigen 2b [12,25) 100%++ 40%+ NI NI NI 
MEL-l Ganglioside 03 2b [12,26,27) 100% +-+++ 10%+ NI Nl NI 
G7A5 Core protein HMW antigen 3 (12) 100% ++ NO NI NI 
AMF-7 Adhesion molecule MACAM-1 3 [28] 95% +-++-H- NO 
AMF-6 HMW glycoprotein (cell spreading 3 [28) 85%++ NO NI NI 
associated) 
D1-12 HLA-DR (28-35-kDa glycoprotein, 3 [12,29] 1%+ NO NI NI 
MHC class II) 
• Percentages refer to numbers of cells within the cytospins showing staining. Increasing intensities of staining are indicated by + to +++; within immunostained sections, +/-
indicates that some but not all melanocytes within immunostained sections react with the antibody; NO, not done; NI, not interpretable-due to stained cel ls in the epIdermIS WIth a 
distribution pattern unlike that of (only) melanocytes, the staining was judged not interpretable; group 1 antibodies discriminate melanocytes in skin sections; group 2a and 2b 
antibodies stain melanoma cells and melanocytes in culture but do not demonstrate melanocytes in frozen skin sections; group 3 antibodies stain only melanoma cells in culture and do 
not discriminate mel ::mocytes in frozen skin sections. 
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vaseline-coated coverslip with the horny layer downward and air-
dried briefly. The tissue was not fixed prior to staining. 
Immunostaining Procedures Indirect immunostaining proce-
dures were used at room temperature under humid conditions. Ace-
tone-fixed material was incubated with a primary antibody in the 
established working dilution for 1 h. In the second step (omitted for 
polyclonal antibody S-100), peroxidase-labeled rabbit anti-mouse 
antiserum (Dakopatts, Glostrup, Denmark) was used in a dilution of 
1: 100 for 30 min. Finally, peroxidase-labeled swine anti-rabbit 
antiserum (Dakopatts) was used in a dilution of 1 : 50 at room tem-
perature for 30 min. Peroxidase activity was detected using 3,3-
amino-9-ethylcarbazole (Sigma) as a substrate. Non-specific stain-
ing was prevented both by pre-incubation with 10% normal swine 
serum (Dakopatts) and by thorough washing in Tris(hydroxy-
methyl)aminomethane-buffered saline throughout the staining 
procedure. Nuclei were counterstained using hematoxilin. The 
same procedure was performed for the monoclonal antibody raised 
in rat, TMH-2. On frozen sections, immunostaining with each 
antiserum was performed on skin specimens from at least three 
patients with vitiligo and one control subject. Furthermore, each 
immunostaining was performed on at least one progressive lesion 
and one stationary lesion. ' 
In split skins, this method was used on biopsies from three pa-
tients. In material from another two patients, a fluorescein isothio-
cynate (FITC)-labeled rabbit anti-mouse secondary antibody (Da-
kopatts) was used to localize the NKl-beteb antigen. In all cases, 
only progressive or stationary lesions were included. After immu-
noperoxidase staining, split-skin preparations were fixed in metha-
nol for 10 min at room temperature. 
Melanocyte densities were evaluated by light microscopic count-
ing of stained cells in combination with measurement of epidermal 
length by an interactive image-analysis system (Kontron Image 
Analysis Division, Miinchen, Germany) in frozen sections. For 
split-skin staining, the surface area was calculated from the diameter 
of the punch biopsy. 
Double staining was performed in either of the following ways. 
Monoclonal OKT-6 (1: 50, detecting Langerhans cells) and poly-
clonal antibody S100 (1: 50) were applied simultaneously for 60 
min at room temperature. Alkaline phosphatase-labeled goat anti-
mouse immunoglobulin (Ig) G and IgM (1: 10) and swine anti-rab-
bit antiserum (1 : 800) were added for 60 min in the second step. 
Finally, rabbit peroxidase anti-peroxidase (1 : 600) was used for 30 
min to detect the polyclonal antibody. Peroxidase activity was de-
tected as above, and alkaline phosphatase was detected with Fast 
Blue BB (Sigma). Alternatively, in the first step monoclonal anti-
body (D 1-12) was added for 50 min. In the following step, alkaline 
phosphatase-labeled goat anti-mouse IgG and IgM (1 : 10) was 
added for 30 min. In the third step, an FITC-labeled monoclonal 
antibody (OKT-6) was added (1 : 100). Rabbit anti-FITC (1: 1000) 
was used in the next step for 20 min. Finally, peroxidase-labeled 
swine anti-rabbit antiserum (1 : 50) was used for 30 min to expose 
the presence of the OKT-6 antibody. Enzyme activities were de-
tected as described above. 
Sources of the primary antibodies are shown in Table II. Most 
were a kind gift ffom Professor Dr. Carrel (Ludwig Cancer Insti-
tute, Lausanne, Switzerland); TMH-2 was a kind gift from Dr. 
Tomita (Tokohu University School of Medicine, Sendai, Japan). 
Others were commercially obtained: NKI-beteb, NKI-C3, G7E2, 
K-1-2-58, 15-75, PAL-M2, PAL-MI, B9-I2-1 , Mel-14, MEL-I, 
G7 A5 , DI-12 (European Organisation for Research and Treatment 
of Cancer Melanoma Group, Professor Dr. S. Carrel); MEL-5, 
MEL-l (ITK Diagnostics, Uithoorn, The Netherlands); NKl-
beteb, NKI-C3, AMF7 (Sanbio, Uden, The Netherlands); HMB-45 
(Enzo Diagnostics, New York); and S-100 (Dakopatts). Other anti-
bodies used were OKT-6 (Ortho-Mune, Heidelberg, Germany); 
FITC-labeled OKT-6 (Ortho-Mune); Alkaline phosphatase-la-
beled goat anti-mouse IgG and IgM (Tago Inc., Burlingame, CA); 
rabbit peroxidase anti-peroxidase (Dakopatts); swine anti-rabbit an-
tiserum (Dakopatts); and rabbit anti-FITC (Dakopatts) . 
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Figure 1. Cytospins of cultured normal human melanocytes stained with 
monoclonal antibodies NKI-bctcb (A), PAL-M2 (B), and 15-75 (C). 
A rrows point to examples of sites of positive staining. Bar, 25 )lm. 
Confocal Microscopy of FITC-Iabeled, NKI-Beteb - Stained 
Split Skins Confocal laser scanning microscopy was performed 
using an MRC-600 confocal microscope (Bio-Rad) and making a 
three-dimensional image of the split skin. The 488-nm line from a 
krypton-argon laser was used to excite the FITC-labeled antibody. 
A three-dimensional image of the observed area was obtained by 
making a stack of several optical sections. By stacking the sections, 
we projected the observations from all sections in one plane. 
RESULTS 
Staining Patterns of Cultured Cells Results of immunohisto-
logic stainings are presented in Table II. The panel was first used to 
stain melanoma cells to determine the optimal working dilution and 
the percentage of cells expected to stain using each antibody. The 
antibodies were found to stain the following percentages of mela-
noma cells: NKl-beteb, NKI-C3, B9-I2-1, Mel-14, MEL-I, G7 A5 
(100%); PAL-M1, AMF-7 (95%); 15-75 (90%); AMF-6 (85%); 
HMB-45 (80%); S-100 (70%); G7E2, PAL-M2 (50%); MEL-5 
(4%); TMH-2, K-1-2-58, D1-12 (1%). 
On normal human melanocytes, positive staining was observed 
for all monoclonal antibodies except G7 A5, AMF-6, AMF-7, and 
DI-12. Five of the antibodies from the panel reacted with all nor-
mal cultured melanocytes in a cytospin, namely, NKl-beteb, MEL-
5, NKl-C3, 15-75, and PAL-M2. The remaining antibodies stained 
variable percentages of cells within the cytospin. This was the case 
for MEL-1 (10%), Mel-14 (40%), G7E2 (40%), S-100 (67%), PAL-
MI (75%), K-1-2-58 (85%), TMH-2 (90%) , B9-I2-1 (99%), and 
HMB-45 (99%). Examples of staining patterns are presented in Fig 
1A-C. NKl-beteb stained the membrane; PAL-M2 showed a peri-
nuclear expression pattern; and 15-75 detected a nuclear antigen. 
VOL. lOa, NO.6 JUNE 1993 
I 
I 




Figure 2. Frozen skin sections. Immunoperoxidase staining patterns in 
non-lesional (A,C) and lesional (B,D) vitiligo skin using NKl-beteb (A,B) 
and MEL-S (C,D) as primary antibodies. M, melanocyte; E, endothelium. 
Bar, 50 J.lm. 
Specificity of Markers for Melanocytes In Situ Results of 
imITlunoperoxidase staining performed on frozen sections from 
control and vitiligo skin are summarized in Table II. The antibodies 
were grouped according to the staining patterns observed. Group 1 
antibodies, staining normal melanocytes irl situ were NKI-beteb, 
MEL-5, TMH-2, HMB-45, NKI-C3, G7E2, and K-1-2-58. Mono-
clonal antibodies NKI-beteb and TMH-2 reacted only with melano-
cytes in skin sections. MEL-5 stained only melanocytes in the epider-
mis but also reacted with endothelium in the dermis. HMB-45 
stained melanocytes extremely weakly. NKI-C3 stained many skin 
cOITlponents other than melanocytes, but melanocytes reacted more 
strongly and could still be distinguished. When used on skin sec-
tions, some group 1 antibodies reacted only with a fraction of 
melanocytes present because other antibodies reacted with more 
cells in serial sections prepared from the same donor. This was true 
for HMB-45, G7E2, and K-1-2-58. G7E2 staining was prominent, 
whereas HMB-45 and K-1-2-58 showed only faint staining. 
Group 2 consists of seven antibodies that stained cultured cells but 
not rnelanocytes ill situ. This is true for 15-75, PAL-M2, B9-12-1, 
PAL-M1, S-100, Mel-14, and MEL-I. None of the antibodies in 
group 2 were useful in localizing melanocytes within the skin. The 
epidernis was either completely negative (group 2a) or positive for 
cells that were not (only) melanocytes (group 2b). Considering the 
results shown in Table II, it thus appears that group 2 antibodies are 
of little value in providing additional evidence for either the pres-
ence or absence of melanocytes in the lesional skin of the patients. 
Group 3 antibodies did not stain normal melanocytes in culture 
and w-ere therefore not used on tissue. Group 1-3 antibodies were 
then used to stain frozen skin sections from three patients with 
vitiligo, irrespective of their staining pattern in control skin. 
Melanocytes in vitiligo skin may express antigens not normally 
found on melanocytes in frozen sections. Results shown in Table II 
show- that no difference in staining pattern was observed between 
control skin and non-Iesional vitiligo skin. Antibodies in groups 2 
and 3 did not show the presence of melanocytes in normally pig-
mented vitiligo skin. Some positive staining was observed in basal 
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cells in vitiligo lesional epidermis using either S-100 or 01-12 
antibodies . However, in double staining with OKT-6 (antibody 
reactive with Langerhans cells), all staining proved to be due to the 
presence of Langerhans cells in the basal layer (results not shown). 
Figure 2A-D illustrates staining patterns for NKI-beteb and MEL-
5 on non-Iesional (Fig 2A,C) and lesional (Fig 2B,D) skin from a 
patient with vitiligo. A normal distribution pattern for melanocytes 
in lesional vitiligo skin was not shown with any of the antibodies 
(Table II). Table III shows melanocyte densities in frozen sections 
from non-lesional skin of patients 1-7, as determined by NKI-
beteb and/or MEL-5 staining in combination with interactive com-
puter analysis for measuring the epidermal length. 
NKI-beteb Staining of Epidermal Split-Skin Preparations 
NKI-beteb was chosen to detect residualmelanocytes in split-skin 
preparations from lesional vitiligo skin. NKI-beteb stains 100% of 
cultured melanocytes (Table II). Moreover, only melanocytes were 
detected in frozen sections with this monoclonal antibody, which is 
thus highly specific for melanocytes. IInmunoperoxidase staining of 
control, non-lesional, and lesional vitiligo split skin is illustrated in 
Fig 3A - D. All samples except the control skin were taken from the 
same patient. Despite the large numbers of melanocytes observed 
using this technique, no consistent differences in either staining 
intensities or morphology between non-lesional vitiligo skin and 
skin from normal subjects were found. On average, only 22 melano-
cytes could be found per 3-mm biopsy (equal to approximately 
8 mm2), as is shown in Table III for patients 8-10. Melanocyte 
densities were not determined in non-Iesional vitiligo split skin 
because the large number of visible melanocytes showed no appar-
ent differences in number from those in control skin. The staining 
illustrated in Fig 3D was found only in the lesional skin of one 
patient. This biopsy was taken from the center of a white patch. 
However, this patch was progressive so that the area from which the 
biopsy was taken had just recently turned white (according to the 
p~tiel~t). This staining pattern probably results from cellular de~ris. 
BIOpSies were then taken from the borderline region inside a leSIOn. 
Figure 4A - C illustrates the three-dimensional image of epidermis 
from another patient, showing perilesional epidermis compared 
with the lesional and non-lesional areas. In the perilesional area, 
lar~e dendri~ic melanocytes were present, although the skin ~rom 
which the biOpsy was taken was clinically observed to be white. 
DISCUSSION 
Differences in the staining patterns of the various antibodies used in 
this investigation, illustrated in Fig 1 for NKI-beteb, PAL-M2, and 
15~ 7~, show that the antibodies detect different phenotypic charac-
tenstlcs ~f melanocytes. This suggests that there is a stro?g chan~e 
of rev~alll?g dormant melanocytes in lesional vitiligo skm. In thiS 
IIlveStigatlOn, antibody 15-75 appeared to react with a nuclear anti-
gen in cultured melanocytes and melanoma cells. This is in contrast 
to the membrane-staining pattern previously reported by Johnson et 
af [35] for this antibody. At present this discrepancy cannot be ex-
plained. Seven of 18 antibodies detected melanocytes in frozen sec-
tions of normal and non-Iesional vitiligo skin; however, melano-
cytes could not be found in lesional skin sections. 
Monoclonal antibodies capable of detecting normalmelanocytes 
in frozen skin sections are NKI-beteb, MEL-5, TMH-2, HMB-45, 
NKI-C3, G7E2, and Kl-2-58. These antibodies comprise group 1, 
as indicated in Table II. Of these monoclonal antibodies, NKI-beteb 
is the most specific for melariocytes in frozen sections and sho~s 
intense melanocyte staining (similar to that in non-leslOnal Skill, 
illustrated in Fig 4A). TMH-2 is also highly specific for ~el~~­
cytes in skin sections. With NKI-C3, melanocytes can be dlscn~­
nated, but non-specific staining is present in frozen sectl.ons; thiS 
antibody gives better results on paraffin sections (17]. Wlth~n the 
epidermis, antibody MEL-5 is specific for melanocytes, but 111 the 
dermis other cell types (endothelial cells) are also detected by thiS 
antibody. Contrary to the findings of Gown et af [18], H~-45 does 
stain melanocytes in frozen sections, albeit very weakly. Like G7E2 
and K-1-2-58, HMB-45 stains only a fraction of the melanocytes 
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Table ill. Melanocyte Densities' 
Patient 
2 3 4 5 6 7 8 9 10 11 12 
Melanocyte density 18/mm 10/mm 22/mm 14/mm 33/mm 9/mm 23/mm NO NO NO NO ND 
(non-lesional) 
Melanocyte density O/mm O/mm O/mm O/mm O/mm O/mm O/mm 1/mm2 2/mm2 7/mm2 ND ND 
(lesional) 
• Melanocyte densities as determined by NKl-beteb and/or MEL-S staining in combination with interactive computer anaJysis to determine cpidcrmal length. Surface arcas were 
calculated from the diameter of the biopsies. Biopsies from patients 1 - 7 were used for data on frozcn scctions; biopsies from patients 8 - 10 wcre used for immunopcroxidase staining 
of split skin; biopsies from patients 11 and 12 were used for confocal laser scanning microscopy of split skin. NO. not determined. 
present,judging from stainings performed with other antibodies on 
serial sections obtained from the same biopsy. 
Because each of the monoclonal antibodies from group 1 is di-
rected against a different antigen (Table II), all accompanying phe-
notypic traits are lost in vitiligo lesions. Group 2 antibodies did react 
with cultured melanocytes but could not be used to distinguish 
melanocytes in skin sections. If expression of the antigen is not 
visible in frozen skin sectio.ns (as in the case of group 2a antibodies), 
this discrepancy could pOSSlbly be explained by a difference between 
in vitro and in vivo circumstances. In culture conditions, cells are 
constantly induced to proliferate, creating circumstances similar to 
those found in "melanoma progression" [361. The rationale for 
using group 2a antibodies in this study is because they are reactive 
with cells of the melanocytic lineage, and it is still not known which 
conditions will induce expression of the accompanying antigens by 
melanocytes in skin sections. Alternatively, the antibody may not be 
specific for melanocytes in the epidermis. Basal epidermal staining 
was observed, but melanocytes could not be distinguished (group 
2b). For example, antibody B9-12-1, directed against major histo-
compatibility complex (MHC) class I molecules [human leukocyte 
antigen (HLA)-B locusl is also expressed by keratinocytes, thus 
melanocyte~ could not be distinguished. As shown in Table II,littie 
information on the presence or absence of melanocytes in vitiligo 
lesions was gained from the use of group 2a or 2b antibodies. 
Group 3 antibodies (G7AS, AMF-6, AMF-7, and Dl-12) showed 
positive staining on melanoma cells but did not stain normal 
melanocytes and can thus be regarded as tumor related. It was there-
fore not surprising that these monoclonal antibodies did not show 
positive staining on skin sections. 
Figure 3. Split-skin preparations obtained from control skin (A) and from 
non-lesional (B) and lesional (C,D) skin biopsics from the samc patient with 
vitiligo and stained with NKI-betcb. Bar, 50 pm. 
Because S-l 00 and D 1-12 both react with epidermal Langerhans 
cells, it was necessary to perform double stainings with the Langer-
hans cell-specific antibody OKT-6. Double staining confirmed 
that the cells with distribution patterns commonly found for 
melanocytes were indeed Langerhans cells in the basal layer. Such 
basally located Langerhans cells in vitiligo lesions have been rc-
ported by others [371 . Antibodies MeI-14 (group 2), G7 AS (group 
3), and AMF-6 (group 3) all detect the high molecular weight 
(HMW) antigen on melanoma cell s and show basal layer staining 
reminiscent of adhesion-molecule staining patterns [38] and need 
further investigation. The fact that only MeI-14 reacts with normal 
human cultured melanocytes may be due to specificity for a differ-
ent epitope than G7AS or AMF-6. 
Our results on skin sections suggest that melanocytes are absent in 
vitiligo lesions. An alternative explanation is that a reduced number 
of otherwise normal melanocytes (thus positive for NKI-beteb) is 
present in vitiligo lesions. Large numbers of melanocytes can be 
detected in split skin, so that a reduction is readily determined. Our 
results indicate that normal amounts of melanocytes with no differ-
ences in staining intensities and morphologies are present in normal 
numbers in non-lesional vitiligo skin (Fig 3A,B). Differences in 
melanocyte morphology observed between Fig 3A and B may be 
attributable to staining artifacts. By the same staining technique, 
only an occasional melanocyte was found in lesional skin (Table III). 
However, in split skin derived from an expanding vitiligo lesion, an 
area of positive staining showing abnormal morphology was found. 
Such areas most likely represent sites of melanocyte destruction. In 
the stationary lesion, where such a process of destruction was 
thought to be long completed, no cellular remnants can be found. 
This prompted us to further investigate the process of postulated 
melanocyte destruction using NKI-beteb with a fluorescent marker 
on perilesional skin taken from the inside of a depigmenting lesion. 
The preparation was obse~ed by c~nfocal microscopy. This t~c~­
I11que offers the opporturuty to project the complete epidernus 111 
one focal plane. Therefore, cellular debris can be distinguished from 
intact cells. Results in one patient indeed confirm the presence of 
degenerated melanocytes in the borderline area within a vitiligo 
lesion. In perilesional skin fr0m another patient, enlarged dendritic 
melanocytes were found in such areas (Fig 4). The finding of such 
melanocytes with altered morphology is in accordance with find-
ings by Iyengar and Misra [39J. Because the biopsies used for this 
investigation were taken from skin that was clinically observed to be 
white, depigmentation may precede melanocyte destruction in viti-
ligo lesions. 
The finding that melanocytes are lost in vitiligo lesions is in 
accordance with electron microscopic observations by others. We 
have added to the evidence for loss of melanocytes in vitiligo lesions 
by showing that other phenotypic characteristics of melanocytes, as 
defined by the antibodies used, are also absent in vitiligo lesional 
skin. Melanocytes found in cultures from suction-blister rooftops 
prepared from lesional vitiligo skin may represent occasional re-
maining pigment cells. Residual tyrosinase activity in the amounts 
reported by Husain et al [111 is unlikely to originate in the few 
melanocytes present in lesional skin. Possibly, melanocytes present 
in hair follicles from pigmented hairs that are often found in lesional 
skin are responsible for such residual tyrosinase activity. In any case, 
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Figure 4_ Images obtained by confocal laser scanning microscopy after 
iDlmunostaining with NKI-beteb. Non-Iesional (A) , perilesional (B), and 
lesional (C) epidermis are represented. For non-Iesional epidermis. nine 
sections of 0.4 11m were stacked. For perilesional and lesional epidermis. 13 
sections of 1 11m were needed to transverse the total epidermis. All biopsies 
were taken from the same patient. The lesion had evolved 6 months earlier 
and remained stationary in its present form. Perilesional skin was taken from 
the borderline area inside the lesion. Bar, 25 ,urn. 
the results presented here indicate that any hypothesis on the etiol-
ogy of vitiligo should involve a mechanism for melanocyte destruc-
tion. 
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